Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 8/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | PYGB | P11216 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15962117 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL14380049 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL12899675 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL14732694 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL12929221 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL12141264 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL13068778 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL24107709 | 0.94 | PYGB (0.42) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL12210250 | 0.94 | PYGB (0.42) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL16126880 | 0.94 | PYGB (0.42) | LGALS8OGAPYGBLGALS1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019071105-A1 | CRYSTALLINE COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-9567589-B2 | NGF aptamer and application thereof | RIBOMIC INC. (JP) | 2017-02-14 | — | — | US | disclosed |